#South Korea #Seoul #Botulinum Toxin #SOLTOX #CELSET

CELSET Introduces SOLTOX to the Global Market

CELSET INC., a prominent Korean biotechnology company specializing in medical aesthetics, has recently announced the launch of SOLTOX, its new botulinum toxin type A brand. This strategic move introduces a significant player into the international medical aesthetics arena, demonstrating the company's commitment to innovation in aesthetic medicine.

Product Overview

SOLTOX is available in two formulations, containing 100 units and 200 units. It stands out with three distinctive technical features: a 900 kDa toxin complex, a freeze-dried formulation, and an advanced purification process. These characteristics embody CELSET's approach to manufacturing, emphasizing controlled processing, product characterization, and pharmaceutical quality.

The 900 kDa complex refers to the size of the botulinum toxin protein complex, which includes associated proteins. It is essential to note that this characteristic does not imply a clinically superior duration of action or efficacy. SOLTOX is provided as a lyophilized powder that must be reconstituted by qualified medical professionals before administration, following the product labeling and local regulations.

Purification is a crucial component of the SOLTOX manufacturing strategy. CELSET employs advanced purification technology in the processing of botulinum toxin type A, focusing on isolating the desired substance from unwanted impurities. The production process also includes controlled manufacturing conditions and quality control measures covering preparation, filling, freeze-drying, and batch evaluation.

Key Features and Manufacturing Excellence

CELSET emphasizes these manufacturing traits as the technical foundation of SOLTOX. The product's positioning highlights the identity of the formulation and the process controls, steering clear of equating manufacturing characteristics with unverified differences in patient outcomes. The brand combines technical information with a concise identity aimed at recognition across the medical aesthetics sector.

The launch of SOLTOX aligns with CELSET's international efforts within the realm of medical aesthetics. Its positioning reflects the growing visibility of Korean biotechnology and aesthetic medical production, as well as the importance of established medical distribution channels and market-specific regulatory frameworks. CELSET recognizes the development of market presence at country level and the establishment of professional relationships as integral to the international presence of the SOLTOX brand.

In expanding its portfolio with SOLTOX, CELSET reinforces its commitment to evidence-based product communication in the field of medical aesthetics. The company prioritizes a cohesive brand presentation and clear information for medical professionals across various markets, ensuring that availability and usage comply with prevalent regulatory stipulations in respective countries.

About CELSET INC.

Established in Seoul, South Korea, CELSET INC. is focused on biotechnology in the medical aesthetics sector. The launch of SOLTOX exemplifies the company's dedication to creating distinctive brands, adhering to manufacturing principles for aesthetic medical products, and fostering professional communication within the global aesthetics industry.

For more information, visit CELSET's official website.